Zykadia
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome 2 cause ALK to fuse to echinoderm microtubule-associated protein-like 4. This activates the ALK kinase domain and downstream signaling pathways responsible for excess cancer cell proliferation. ALK gene rearrangements are found more commonly in younger, non-smoking NSCLC patients and make up 3–5% of all NSCLC cases.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Zykadia : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
11 Figure 1: Datamonitor Healthcare’s drug assessment summary for Zykadia in non-small cell lung cancer
12 Figure 101: Datamonitor Healthcare’s drug assessment summary for ensartinib in non-small cell lung cancer
14 Figure 102: Datamonitor Healthcare’s drug assessment summary for ensartinib in non-small cell lung cancer
LIST OF TABLES
5 Table 1: Zykadia drug profile
7 Table 2: Zykadia pivotal trial data in non-small cell lung cancer
15 Table 3: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
17 Table 4: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the